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Vascular interventions account for 61% of hospitalization costs,
overall. CONCLUSIONS: Rates and costs of vascular events/
interventions are high in patients with PAD, and increase with
identiﬁable risk factors. Risk factor modiﬁcation and prevention
efforts are needed to lessen the burden of atherothrombotic
disease for PAD patients, and society.
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OBJECTIVES: To determinate the co-morbidity and direct costs
of stroke among Spanish population in daily medical practice.
METHODS: A retrospective study was performed based on data
from patients attended for stroke, aged >30 years, from ﬁve
Spanish primary care centres (PCC) and two hospitals in 2006.
Main analysed variables were: age, sex, general or speciﬁc
(cardiovascular and others) events/co-morbidities, use of drugs,
clinical parameters (according to NCEP-ATPIII) and direct costs
(pharmacy, derivations, visits, emergencies, procurement, and
hospitalisation). An ANCOVA analysis and logistic regression
were used to ﬁt the model. RESULTS: Of 57.026 patients
included in the analysis, 4.5% (n = 2.585, CI95%: 4.3–4.7%)
suffered stroke. The incidence of stroke was 220 new cases/
100.000 populations. Main differences between patients suffer-
ing stroke and control group were: age (72.5 vs. 53.5), men
(58.2% vs. 44.6%), events/year (7.9 vs. 4.8), visits/year (15.8 vs.
8.1), poli-pharmacy (91.5% vs. 53.6%), use of statins (85.0% vs.
32.2%), antiagregants and/or anticoagulants (78.9% vs. 28.0%),
p < 0.001 for all differences. Stroke had an independent relation
with age (odds ratio, [OR] = 1.4), male gender (OR = 2.3), dia-
betes (OR = 1.6), hypertension (OR = 1.5), smoking (OR = 1.5),
alcohol abuse (OR = 1.4), depression (OR = 1.4), dyslipidemia
(OR = 1.3) and dementia (OR = 1.2). Some of the results were:
systolic pressure (134.1 vs. 127.6 mmHg), body mass index
(28.9 vs. 27.9 kg/m2) and LDL-cholesterol (116.4 vs. 126.2 mg/
dl), in presence/absence of stroke, p < 0.001. The average of
annual costs of stroke was €2590.36 vs. €985.26, p < 0.001.
After the correction of the logistic model results did not change:
€1774.33 (IC: 1720.10-€1.828.55) vs. €1021.98 (IC: 1010.92-
€1033.03€, p < 0.001. All components of costs were higher in the
stroke group. CONCLUSIONS: Prevalence and incidence are
similar to that published in the literature. Patients that demanded
assistance for stroke had a higher number of co-morbidities and
a higher total cost/patient/year. Therapeutic objectives could be
improved, mainly in primary prevention of cardiovascular risk
factors.
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OBJECTIVES: Clopidogrel (in addition to aspirin) for the treat-
ment of all patients with acute coronary syndromes (ACS) was
recently approved for additional reimbursement under the Aus-
tralian Pharmaceutical Beneﬁts Scheme. We sought to estimate
the implications of this approval for the Australian health care
system. METHODS: A Markov model to determine cost-
effectiveness was constructed by extrapolation of data from the
Australian Acute Coronary Syndromes Prospective Audit
(ACACIA) registry (n = 2553) in the ﬁrst model cycle, and the
Reduction in Atherothrombosis for Continued Health
(REACH) registry (n = 2567) in subsequent model cycles. Efﬁ-
cacy data were drawn from the Clopidogrel in Unstable Angina
to Prevent Recurrent Events (CURE) trial. Drug, cardiovascular
disease and hospitalisation costs were sourced from the litera-
ture and health care reimbursement fees. These were updated as
required using Australian health price indices. An annual dis-
count rate of 5% was applied to all costs and effects beyond one
year in accordance with reimbursement guidelines. Data regard-
ing the prevalence of ACS was estimated from published
national Australian epidemiological and demographic data. As
clopidogrel is already reimbursed for patients who have taken
aspirin prior to their event, or who cannot take aspirin due to
allergy or intolerance, literature was reviewed to estimate this
population. RESULTS: The estimated number of newly eligible
patients ranged annually from 48,100 to 62,700 over ﬁve years.
The expanded treatment coverage was estimated to prevent an
additional 12,400 major cardiovascular events (comprising
myocardial infarctions, strokes and deaths) in the ﬁrst ﬁve
years, leading to a saving of A$175 million in health care costs
arising from avoided hospitalisation, procedures and medica-
tions. This has major resource implications for the Australian
health system in terms of stafﬁng, bed availability and emer-
gency admissions. CONCLUSIONS: The imminent implemen-
tation of unrestricted access to clopidogrel plus aspirin for all
ACS patients is likely to lead to signiﬁcant health and cost-
savings for Australia.
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OBJECTIVES: To determine the co-morbidity inﬂuence and the
direct cost according to cardiovascular risk levels (CRL) in
patients older than 55 years appertaining to population setting
and in clinical practice. METHODS: Multicentric design, real-
ized beginning from registers of subjects 55 years appertaining
to a seven centres of primary care (year 2006). The calculation of
the CRL was effected using Framingham-Wilson equation: low
risk (<10), moderate (10–19), high (20–29) and very high (30).
Main measures: general (age, gender, etc.), cardiovascular
co-morbidities (CIAP-2), cardiovascular events-CVE (criteria:
NCEP-ATP III), Charlson-index (patient severity) and cost
model. The general morbidity charge was measured beginning
from Adjusted-Clinical Groups (http://www.acg.jhph.edu).
Fixed/semiﬁxed costs were considered (structure, salary, services)
and variable ones (diagnostics/therapeutics requests, referrals,
drugs). An analysis of logistical regression and the covariance
(ANCOVA) was affected for the correction of the models
(procedure: Bonferroni), according to the recommendations of
Thompson-Barber. Program SPSSWIN; p < 0.05. RESULTS:
From 24,441 subjects older than 55 years, were attended 12,828.
The 30.1% (IC 95%: 29.3–30.9%) showed a high/very high
CRL. All studied variables in bivariant relation were related to
CRL. Increase of CRL was associated as an independent way to
man (OR = 7.1), diabetes (OR = 6.8), smoking (OR = 5.8),
hypertension (OR = 2.3), dislipemia (OR = 1.9), obesity
(OR = 1.4), CVE (OR = 1.3) and age (OR = 1.2), p < 0.001). The
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